Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...

In the study, "Efficacy and Safety of Twice-Yearly Depemokimab in Chronic Rhinosinusitis with Nasal Polyps (ANCHOR-1 and ANCHOR-2)," published in The Lancet, researchers conducted randomized ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...